Table 1 Characteristics of trials included in the meta-analysis
Kiès et al. 2005 [9] | Ghali et al. 2007 [2010] | Hoppe et al. 2007 [11] | Fantoni et al. 2008 [12] | Mangiavacchi et al. 2008[13] | |
|---|---|---|---|---|---|
No. of patients randomized | 97 | 1211 | 813 | 355 | 447 |
Age, mean, y | 63 | 66 | 67 | 63 ± 9 | 65.7 ± 9.7 |
Men, % | 77 | 67 | 74 | 75 | 81 |
LVEF, mean, % | 22 | 22 | 25 | 21.2 ± 6.2 | 28.9 ± 6.1 |
NYHA functional class, range | III-IV | III-IV | III-IV | III-IV | II-IV |
Ischemic cardiomyopathy, % | 62 | 55 | 40 | 47 | 54 |
QRS duration, mean, ms | 176 | 158 | 160 | 163 | 166 |
ACEI inhibitor or ARB, % | 88 | 88 | 95 | 98 | 99.3 |
insulin-treated diabetic patients, (%) | 9 (28.1) | - | 85 (10.5) | 57 (40.4) | 29 (31.9) |
Follow-up, randomized, mo | 6 | 12 | 36.4 | 35 | 36 |